Litigation Summary and Analysis: Novartis Pharmaceuticals Corporation v. Cipla USA Inc. (D.N.J.) | Case No. 1:26-cv-00272
Executive summary. The action is a Hatch-Waxman patent infringement suit in the District of New Jersey brought by Novartis Pharmaceuticals Corporation against Cipla USA Inc. under case number 1:26-cv-00272. The complaint and docket events needed to produce a complete infringement-and-procedure analysis (asserted patents, Orange Book drug details, Paragraph IV theory, requested relief, claim construction posture, and current status) are not present in the provided material, so no accurate, citation-backed litigation summary can be generated.
What patents are asserted in Novartis v. Cipla USA Inc. 1:26-cv-00272?
Featured-snippet answer. Not determinable from the provided information.
Which patent numbers and claims does Novartis assert?
Not determinable. A litigation analysis requires the asserted patent list from the complaint (typically the “List of Patents” section and the infringement counts referencing specific claims).
Are patents for the active ingredient, formulation, or method-of-use asserted?
Not determinable. Hatch-Waxman complaints typically split asserted patents into drug substance, formulation, and/or method-of-use. That breakdown cannot be derived from the case caption…
